HARVEY RUBIN, MD
Osteopathic Medicine at Spruce St, Philadelphia, PA

5723316, Mar 3, 1998

Mar 31, 1994

8/221171

Barry S. Cooperman - Penn Valley PA
Harvey Rubin - Philadelphia PA
Norman Schechter - Philadelphia PA
Zhi Mei Wang - Philadelphia PA

Trustees of the University of Pennsylvania - Philadelphia PA

C12N 1500, C12N 510, A61K 3843

435 692

The invention provides analogues of. alpha. -1-antichymotrypsin having amino acid substitutions at position 358. . alpha. -1-antichymotrypsin analogues having amino acid substitutions at positions 356-361 and analogues having amino acid substitutions at positions 356-361 wherein the amino acid at position 358 is substituted are also within the scope of the invention. These analogues exhibit chymase inhibitory activity. Also provided are novel. alpha. -1-antichymotrypsins having an N-terminal extension of methionine-alanine-serine or alanine-serine. Expression vectors for the production of. alpha. -1-antichymotrypsins are also provided. The present invention also provides host cells and cell cultures capable of expressing analogues of. alpha. -1-antichymotrypsin, as well as protein preparations from the host cells. Methods of producing and using the analogues of. alpha.

4880512, Nov 14, 1989

Oct 14, 1988

7/259508

Paul A. Cornelius - Philadelphia PA
Robin M. Hochstrasser - Philadelphia PA
Neville R. Kallenbach - Philadelphia PA
Harvey Rubin - Philadelphia PA
George J. Todaro - Seattle WA

Kollmorgen Corporation - Simsbury CT

B01J 1908

20415761

A novel irradiation process and products made thereby. The process treats biological media such as blood fractions, genetically engineered protein products and vaccine preparations. The process photolyzes nucleic acids in preference to proteins in the media, e. g. , it inactivates DNA- or RNA-containing pathogens while leaving the proteins substantially intact or functional. In general, the process comprises irradiating the medium with pulsed light of wavelength and flux selected so that (1) the nucleic acids in their ground state absorb radiation and thereby rise to an excited state or states, (2) the nucleic acids in their excited states absorb radiation and thereby rise to higher energy states and undergo photolysis, and (3) the proteins in their ground or their excited states do not absorb sufficient radiation to undergo substantial photolysis. It is surprising and unexpected that nucleic acids in their excited states undergo efficient photolysis whereas proteins under the same conditions in the same medium are kept substantially intact.

5459063, Oct 17, 1995

Oct 14, 1993

8/136743

Barry S. Cooperman - Penn Valley PA
Harvey Rubin - Philadelphia PA
Jerome Salem - Cheltenham PA
Alison L. Fisher - Blue Bell PA

The University of Pennsylvania - Philadelphia PA

C12N 902, C12N 1553

4352523

This invention relates to the ribonucleotide reductase of Plasmodium falciparum (Pf RR), to the subunits of Pf RR (Pf R1 and Pf R2), and to compounds comprising peptides derived from the Pf R2 C-terminus sequence that inhibit the action of protozoal RR. The invention provides a method for the prevention and treatment of malaria caused by P. falciparum by controlling the proliferation of P. falciparum comprising administering to a patient at least one peptide according to the invention. Antimalarial compositions are provided which comprise a pharmaceutically acceptable carrier and at least one peptide according to the invention which inhibits the P. falciparum ribonucleotide reductase reduction of ribonucleotides to 2'-deoxyribonucleotides. Also provided are methods for diagnosing malaria and for screening potential antimalarial agents.

5637479, Jun 10, 1997

May 5, 1995

8/435480

Harvey Rubin - Philadelphia PA
Barry Cooperman - Penn Valley PA

The Trustees of the University of Pennsylvania - Philadelphia PA

C07K 14435, C07K 1481, C12N 1515

435 692

A method of producing a recombinant ACT analogs having modulated DNA binding capability is provided. Recombinant ACT analogs having modulated DNA binding capability are also provided.

5834279, Nov 10, 1998

Mar 3, 1997

8/813940

Harvey Rubin - Philadelphia PA
Fude Yang - Philadelphia PA
David Avarbock - Lansdale PA
Sean Curran - Mountaintop PA

Trustees of the University of Pennsylvania - Philadelphia PA

C12N 1531, C12N 121, C12N 902, C12N 903

435189

Nucleic acid molecules that encode R2 subunit protein and topoisomerase I protein, fragments thereof, recombinant expression vectors and host cells are disclosed. Oligonucleotide molecules with nucleotide sequences complimentary to a nucleotide sequence encode R2 subunit protein and topoisomerase I protein are disclosed.

5367064, Nov 22, 1994

Jan 15, 1993

8/005908

Harvey Rubin - Philadelphia PA
Zhi M. Wang - Philadelphia PA
Barry S. Cooperman - Penn Valley PA
Norman Schechter - Philadelphia PA

The Trustees of the University of Pennylsvania - Philadelphia PA

C07H 2104, C07K 1300, C12N 1522

536 232

The invention provides. alpha. -1-antichymotrypsin and protein preparations comprising human. alpha. -1-antichymotrypsin produced by E. coli cells transformed with a DNA sequence encoding human. alpha. -1-antichymotrypsin. The invention also provides methods for producing. alpha. -1-antichymotrypsin. The invention further provides analogues of. alpha. -1-antichymotrypsin that exhibit antichymotrypsin, anti-trypsin and anti-thrombin activity and methods of producing the analogues.

5252725, Oct 12, 1993

Jul 24, 1991

7/735335

Harvey Rubin - Philadelphia PA
Zhi M. Wang - Philadelphia PA

The Trustees of the University of Pennsylvania - Philadelphia PA

C07H 2100, C07K 300, C12N 1509, A61K 4505

536 235

The invention provides. alpha. -1-antichymotrypsin and protein preparations comprising human. alpha. -1-antichymotrypsin produced by E. coli cells transformed with a DNA sequence encoding human. alpha. -1-antichymotrypsin. The invention also provides methods for producing. alpha. -1-antichymotrypsin. The invention further provides analogues of. alpha. -1-antichymotrypsin that exhibit antichymotrypsin, anti-trypsin and anti-thrombin activity and methods of producing the analogues.

5612194, Mar 18, 1997

Jul 19, 1994

8/276936

Harvey Rubin - Philadelphia PA
Barry Cooperman - Penn Valley PA
Norman Schechter - Philadelphia PA
Michael Plotnick - Havertown PA
Zhi M. Wang - Philadelphia PA

Trustees of the University of Pennsylvania - Philadelphia PA

A61K 3855, A61K 3857, C07K 1481, C12N 1515

435 692

A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.